Abstract Information is lacking on the effects toxic environmental metals may have on the 26S proteasome. The proteasome is a primary vehicle for selective degradation of damaged proteins in a cell and due to its role in cell proliferation, inhibition of the proteasome has become a target for cancer therapy. Metals are essential to the proteasome's normal function and have been used within proteasomeinhibiting complexes for cancer therapy. This study evaluated the association of erythrocyte metal levels and proteasome chymotrypsin-like (CT-like) activity in age-and racematched prostate cancer cases (n061) and controls (n061). Erythrocyte metals were measured by inductively coupled plasma mass spectrometry (ICP-MS). CT-like activity was measured by proteasome activity assay using a fluorogenic peptide substrate. Among cases, significant correlations between individual toxic metals were observed (r(arseniccadmium)00.49, p<0.001; r(arsenic-lead)00.26, p00.04, r(cadmium-lead) 0.53, p<0.001), but there were no significant associations between metals and CT-like activity. In contrast, within controls there were no significant associations between metals, however, copper and lead levels were significantly associated with CT-like activity. The associations between copper and lead and proteasome activity (r(copper-CT-like) 0−0.28, p 00.002 ; r(lead-CT-like) 0 0.23, p 00.011) remained significant in multivariable models that included all of the metals. These findings suggest that biologically essential metals and toxic metals may affect proteasome activity in healthy controls and, further, show that prostate cancer cases and controls differ in associations between metals and proteasome activity in erythrocytes. More research on toxic metals and the proteasome in prostate cancer is warranted.
Introduction
Little is known about the effects that environmental metal exposure may have on proteasome activity within the human body. The proteasome is a multi-protein complex of both permanent and transient interacting proteins, some of which require essential metals such as zinc to function [1, 2] . The proteasome is responsible for the degradation of proteins involved in the regulation of cell differentiation, proliferation, signal transduction, and apoptosis, as well as the destruction of misfolded and damaged proteins. Dysfunction of the proteasome and the ubiquitin-proteasome pathway has been implicated in several diseases including cancer [3] [4] [5] [6] . Inhibition of proteasome activity is associated with tumor cell death [7] . Several proteasome inhibitors currently under development as chemotherapeutic agents contain metals or metal complexes [8] [9] [10] . Both biologically essential metals, for example, copper [7, 11, 12] , and nonessential metals including cadmium [13] , have shown some efficacy as proteasome inhibitors in cell culture.
This study aims to determine whether erythrocyte arsenic (As), cadmium (Cd), copper (Cu), lead (Pb), or zinc (Zn) levels are associated with chymotrypsin-like (CTlike) proteasome activity in prostate cancer patients and control subjects. CT-like activity is considered to be the primary measure of the degradation potential of the proteasome, although trypsin-and caspase-like activities have been shown to be important in protein degradation as well [14] . We hypothesize that there will be differences in the associations of metals and CT-like proteasome activity in men diagnosed with prostate cancer when compared to men without prostate cancer.
Materials and Methods

Blood Samples
Erythrocytes were separated from peripheral blood samples of African American and white prostate cancer cases and controls as part of the Gene-Environment Interaction in Prostate Cancer Study (GECAP) [15] and were stored at −20°C. A subset of GECAP cases (n061) and controls (n061) were selected for study here, and were matched on race, age (±2 years) and date of blood draw (±1 year).
Metals
Metal levels were measured by inductively coupled plasma mass spectrometry (ICP-MS). For each sample, 100 μl of erythrocyte was mixed with 1 ml of concentrated nitric acid (Optima Grade from Fisher) in acid-washed and dried polyethylene tubes, and incubated overnight at room temperature. The following day samples were heated for 15 min at 70°C. For As, Cd, Cu and Pb analysis, 0.3 ml of the digested sample was diluted to 3 ml. For Zn analysis, 0.07 ml of the digested sample was diluted to 3 ml. Internal standards used were Y and In. Calibration standard stock solutions were purchased from VWR or Perkin-Elmer. HPLC-grade water was used for all the measurements. For samples and standards, the final nitric acid concentration was kept below 20%. Samples were analyzed in a PerkinElmer Sciex Elan 9000 ICP-MS with a cross-flow nebulizer and Scott type spray chamber. The RF power was 1,000 and the argon flow was set at 0.92 l/min. The detection limits for the different metals under these experimental conditions were: 0.004 ppb for As, 0.005 ppb for Cd, 0.01 ppb for Cu, 0.01 ppb for Pb, and 0.5 ppb for Zn. The reported ICP-MS data are the results of two to three replicate measurements of at least two separately digested samples from each erythrocyte sample.
Proteasome Activity
Proteasome activity was determined by the method previously described [11] . Briefly, proteins were extracted from the erythrocytes in a lysis buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5 % NP-40, and 0.1 % of protease inhibitor cocktail) for 30 min at 4°C. Afterwards, the lysates were centrifuged at 14,000×g for 20 min, and the supernatants were collected and protein concentration was measured. From each erythrocyte sample, 15 μg of total protein was incubated with 40 μM of fluorogenic peptide substrates Suc-Leu-Leu-Val-Tyr-AMC (for CT-like activity) in 100 μl assay buffer (20 mM Tris-HCl, ph 7.5) for 2 h at 37°C. After incubation, production of hydrolyzed fluorescent AMC groups was measured using Wallac Victor 3 multilabel counter with an excitation filter of 365nm and an emission filter of 460 nm. Matched case and control pairs were run together in one of five separate batches.
Statistical Analysis
We used t-tests to determine differences between groups and Pearson correlation coefficients were used to assess associations between individual metals and CT activity. Partial correlations took into account race and CT batch. Multivariate linear regression models were run separately for cases and controls and included CT-like activity as the dependent variable and all metals and CT batch as the independent variables. Since cases and controls were matched on race and age and these two variables did not appear to modify results, they were not included in final regression models. Statistical significance was set at p<0.05.
Results
Cases and controls ranged in age from 42 to 75 years of age and did not differ in race or age by design. There were no significant differences in mean metal levels or CT-like activity between cases and controls, although cases had slightly lower zinc (12,132 vs.12,496 ppb, p00.48), higher copper (892 vs. 756 ppb, p00.33), and higher CT-like activity (6,103 vs. 5,601 RFU, p00.38) as expected [16] [17] [18] .
As Table 1 shows, we first evaluated correlations between individual metals, as metals may work in concert or be antagonistic to one another with regard to their effects on the proteasome. Among cases there were significant correlations between metals, while in controls there were none. In cases, arsenic was significantly associated with cadmium (r00.49, p<0.001), lead (r00.26, p00.04), and zinc (r0 0.35, p00.006) and cadmium was positively correlated with lead (r00.53, p<0.001). Further, Table 1 shows associations between metals and CT-like proteasome activity. There were no significant associations between individual metals and CT-like activity in cases. In healthy controls, however, higher copper was associated with lower CT-like activity (r0−0.38, p00.003), while higher lead, a non-essential metal and toxicant, was associated with higher CT-like activity (r00.29, p00.026).
In multivariable linear regression models which included all metals and controlled for batch (Table 2 ), significant associations remained between copper and lead and proteasome activity in controls. There were no significant associations between metals and CT activity in cases.
Discussion
In this study of erythrocyte metal levels and proteasome activity, we observed significant correlations between the non-essential toxic metals, arsenic, cadmium and lead, in prostate cancer cases but not in controls. Further, we did not observe significant associations between metals and CT-like activity in cases but did observe such associations in controls. We observed a significant inverse association between copper, an essential metal, and proteasome activity, and a significant positive relationship between lead, a non-essential metal, and proteasome activity in controls. These findings suggest that in healthy subjects both essential and non-essential metals may affect proteasome activity. In addition, metal-proteasome associations appear to differ between prostate cancer cases and controls. The correlation of metals within cases but not controls is of interest. As noted by Schrauzer [19] , several metals including As, Cd, and Pb can act as selenium-antagonists and can result in the inactivation of selenium (Se), a metal commonly studied for its prostate cancer protective effects. Studies by the same author with others [20, 21] , using prostate tissue collected during autopsy, showed that the ratio of Cd to Se was higher in older men compared to younger men, suggesting that changes in metal ratios over the lifespan may play a role in age related tumors such as prostate cancer. In another study [22] , lower iron and Zn levels were associated with biochemical recurrence of prostate cancer, while, Cd and Se levels did not differ between those with and without recurrence. Together these findings suggest that multiple metals may be involved in prostate cancer etiology and may play different roles throughout the course of the disease.
The ability of copper to inhibit proteasome activity has been reported [7] and copper complexes have been shown to be effective proteasome inhibitors [11, 23] . Our results suggest that, in healthy individuals, copper may be a natural inhibitor of the proteasome, but in prostate cancer cases the ability of copper to inhibit proteasome activity may be lost as part of the disease process. However, high copper levels are known to occur in cancer patients [17] and our lack of association between copper and CT activity in cases may be due to non-proteasome related cancer processes that cause and/or require increases in copper.
In terms of our finding of a positive association between lead and proteasome activity in controls, Grunberg-Etkovitz et al. [24] have shown that lead increases proteasome activity in neuroblastoma cell lines, and work by Guo et al. [25] and Bardag-Gorce et al. [2] suggests that delta-aminolevulinic acid dehydratase (ALAD) may interact with the proteasome. ALAD is responsible for the second step of heme synthesis. Lead has long been known to inhibit ALAD and ALAD inhibition has been used as a biomarker of lead exposure [26] . It has also been suggested that ALAD is a natural inhibitor of proteasome activity [25] . Lead may inhibit ALAD or interfere with other proteins that make up or interact with the proteasome, causing increases in proteasome activity. A lack of association between lead and CT-like activity in prostate cancer cases again suggests that the proteasome may change or function differently in men who develop prostate cancer than in men who are disease-free.
More work is needed to understand how essential metals and non-essential metals affect the normal proteasome and how differences or changes in these metal-proteasome interactions may play a role in prostate cancer.
